ABSTRACT The production of hybridomas between immunologically activated T cells and malignant T-cell lines offers a potentially unlimited source of soluble T-cell-derived products. Recently, human T-T hybrids have been described; however, their use has been hampered by slow growth and chromosomal instability due at least in part to the presence of thymidine in the traditional hypoxanthine/aminopterin/thymidine (HAT) selection medium. In this report, we describe the development of a rapidly growing hypoxanthine phosphoribosyltransferase-deficient human T-cell line designated J3R7, the use of azaserine/hypoxanthine (AH) medium as an alternative selection medium to HAT medium, and the production of functional T-T hybrids by using the J3R7 line and the AH selection technique. Hybrids selected in AH medium were 4-fold greater in number and 3-fold faster in growth rate than hybrids grown in HAT medium. No stable clones were obtained from HAT cultures whereas AH-derived hybrids could be readily cloned by the method of limiting dilution. Evidence for hybridization included (i) the presence of approximately twice the number of chromosomes in hybrids than in J3R7 cells; (ii) the presence on hybrid cells of the Leu-3a surface antigen, present on normal helper T cells but not on J3R7 cells; (iii) the expression of HLA antigens of both the normal T-cell partner and the J3R7 line; and (iv) the constitutive secretion of interleukin 2 from multiple hybrid clones but not from the J3R7 cell line. Thus far, these clones have maintained their rapid growth, chromosome number, surface phenotype, and constitutive secretion of interleukin 2 for 4 months.
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T lymphocytes produce a variety of immunologically active mediators (lymphokines) on stimulation with antigens or mitogens (1, 2) . These mediators can be divided into two broad categories: antigen nonspecific, such as growth factors for T cells (interleukin 2, IL-2) and B cells (3) , and antigen-specific helper and suppressor factors (4) . Due to the limited availability of these factors, knowledge of their structure and function lags far behind that of immunoglobulin, the major B-cell product. Typically, the T-cell products are derived from bulk cultures ofnormal lymphocytes stimulated with mitogens such as phytohemagglutinin (PHA) or concanavalin A (Con A). Although this approach has yielded biologically active factors, the presence of multiple lymphokines as well as the mitogens themselves have hindered large-scale preparation of homogeneous material. In mice, the propagation of T-cell clones in vitro has overcome some ofthese problems (5) . In man, however, such clones have been difficult to maintain and have not yet proved to be reliable sources of lymphokines.
The use of T-T hybridomas produced by the fusion of an activated T cell with a malignant T-cell line offers the theoretical advantages ofa single cell source offactor, rapid and continuous growth in the absence of exogenous growth promoters, and an unlimited supply ofproduct free ofmitogen. This technique has been used successfully for the production of murine T-cell factors (5, 6) . Although reports of human T-T hybrids have appeared (7-10), their utility has been limited by slow growth rates and chromosomal instability. It seems likely that a major factor in the problems encountered with human T-T hybrids is the presence of thymidine in the culture medium, which is known to inhibit the growth of T-cell lines (11) . In this communication, we report a rapidly growing 6-thioguanine (SGua)-resistant Tcell line, a method for the selection of T-T hybrids that avoids the inhibitory effects of thymidine, and the use of this method for the production of IL-2-secreting human T-T hybridomas.
MATERIALS AND METHODS
Cell Lines. A SGua-resistant human T-leukemia cell line, CEMT3 (a subclone derived from a line provided by Warner Greene, National Institutes of Health), was initially used as a fusing parent to produce T-T hybrids. A second permanent Tcell line, J3R7, was derived from the Jurkat human T-leukemia cell line (provided by R. Levy, Stanford University). The Jurkat cells were placed in RPMI 1640 medium (GIBCO)/25 mM Hepes/2 mM L-glutamine/10% fetal calf serum/i ,uM SGua (Sigma) and grown in humidified 95% air/5% CO2 at 37°C. The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. X 107 mutant tumor cells were mixed in 1 ml of 50% (vol/vol) polyethylene glycol (Mr, 1,500; BDH Chemicals, Poole, England) in RPMI 1640 over 1 min. The suspension was centrifuged for 3 min at 500 X g. After 8 min, the cell pellet was suspended in 1 ml of RPMI 1640 with slow mixing over 1 min, followed by addition of 6 ml of RPMI 1640/10% fetal calf serum. The cells were then pelleted at 250 X g for 10 min, and the pellet was washed twice in RPMI 1640/10% fetal calfserum. After this, the cells were suspended in either RPMI 1640/25 mM Hepes/2 mM glutamine/10% NCTC 109 (Microbiological Associates, Walkersville, MD)/15% fetal calf serum/100 ,M hypoxanthine/100 nM aminopterin/16 AM thymidine/10 ,M deoxycytidine (Sigma) (HAT medium) or RPMI 1640/25 mM Hepes/2 mM glutamine/15% fetal calf serum/100 ,M hypoxanthine/azaserine (1 Ag/ml) (Sigma) (AH medium). The cells were cultured in 24-well trays at a concentration of 106 tumor cells per well in a 1-ml volume with a feeder layer of 2 x 105 adherent cells per well. The cultures were maintained at 370C in humidified 95% air/5% CO2. After 10 days, the medium was altered by removing aminopterin or azaserine, respectively. In general, the medium was changed every 3 A standard IL-2 preparation used for comparison was derived from MLA 144, a gibbon leukemia line that constitutively produces IL-2 and has been shown to support murine and human IL-2-dependent T-cell clones (14) .
Cell Surface Marker Analysis. Monoclonal antibodies antiLeu-l, anti-Leu-2a, anti-Leu-3a, and anti-Leu4 were obtained from Becton-Dickinson (Mountain View, CA). T-cell lines and hybridomas were analyzed for the expression ofLeu 1-4 T-cellspecific antigens by using these monoclonal antibodies in combination with a cytofluorograph (FACS III; Becton-Dickinson FACS Systems) as described (15) .
RESULTS
In initial experiments, the CEMT3 line was fused with Con Aactivated normal T cells. After 6 chromosomes compared with 40-46 in the CEMT3 line. Analysis of the cell surface by indirect immunofluorescence using monoclonal antibodies revealed the presence on 90% ofhybrid cells of the Leu-4 T-cell marker, which was absent from the CEMT3 line. Seven of 24 supernatants from different lines secreted IL-2, based on the ability ofsupernatants from these lines to support the growth of IL-2-dependent murine and human T cells (data not shown). Although growth of these lines was maintained for an additional 6 months, the doubling time was slow (5 days), and five ofseven lines stopped secreting IL-2 after 3 months. Analysis ofthese lines showed a significant reduction in the number of chromosomes-from a mean of 80 at 6 wk to a mean of 60 at 16 wk. Although multiple attempts to isolate a secreting hybrid clone by the limiting-dilution technique resulted in growing cells, no IL-2-secreting clones were obtained.
To address the problem of instability of lines, we developed a SGua-resistant T-cell line, J3R7, derived from the Jurkat human cell line. This line grew more rapidly than CEMT3; however, in the presence ofthymidine, the growth rate of both lines slowed by 60-90% (data not shown). In preliminary experiments, T-T hybrids were produced with the J3R7 line and mitogen-activated T cells and, although the doubling time ofthese hybrids was less than those of CEMT3-derived hybrids ( HAT medium (Table 1) . Cells growing in AH medium had a doubling time of approximately 48 hr compared with 72-120 hr for cells growing in HAT medium. As shown in Fig. 1 , analysis of growing hybrid cells revealed 70-90 chromosomes compared with 40-45 in J3R7 cells. Expression of the Leu-3a marker (Figs. 2 and 3) , and the presence of HLA-A and -B antigens of both J3R7 and the normal T-cell partner confirmed hybridization. Thus, the Jurkat line has HLA-A3, -Aw32; -B8, -B13, -Bw4 and the normal donor has HLA-A1, -A3; -B8, -Bw45, -Bw6. The hybrid cells have HLA-A1, -A3, -Aw32; -B8, -B13, -Bw45, -Bw6. Unlike the Leu-3 and HLA-A, -B antigens, the Leu-1 and Leu-4 pan-T markers were expressed by the J3R7 line and all J3R7-derived hybrids and, hence, were not informative.
Although the J3R7 cells did not produce IL-2, 4 of20 hybrids tested secreted IL-2 in the concentration range ofthe MLA 144 gibbon line. As shown in Fig. 4 , the titer of IL-2 in one supernatant of a J3R7-derived hybrid is slightly less than that of the MLA-144 gibbon cell line. After 16 wk of continuous culture, there has been no detectable chromosomal loss or decrease in IL-2 activity in the supernatants of parent hybrids from J3R7 fusions; 12 wk after fusion, clones were obtained by the limitingdilution method. In contrast to our experience with hybrids derived from CEMT3 cells, clones obtained from J3R7-derived hybrids continued to secrete IL-2 up to the time of submission of this report (fable 1, Fig. 5 ). As shown in Fig. 5 , the IL-2 activity from some clones exceeded that obtained from parent cultures. The cloning efficiency was approximately 50% at a limiting-dilution level of one-half cell per well (Table 1) .
DISCUSSION
We have demonstrated the production of T-T hybridomas secreting IL-2 from the fusion ofactivated normal T cells with two mutant T-cell lines, CEMT3 and J3R7. In the initial fusions with CEMT3, a major problem was slow growth rate, probably due to the intrinsically slow growth rate of CEMT3 and the inhib- itory effect ofthymidine. A second problem was progressive loss offunctional activity. After 6 months of continuous culture and multiple attempts to isolate functional hybrid clones from CEMT3 fusions, a major portion of hybrids that secreted IL-2 were lost. This was attributed to chromosomal instability as reflected by a reduction in the number of chromosomes.
These problems were approached first with the development ofa different SGua-resistant T cell line, J3R7, which has a doubling time of 24 hr. Second, a different selection medium was used in the later fusions with J3R7, which avoided the inhibitory effects ofthymidine. Most mammalian cells have two pathways to synthesize DNA, the de novo pathway, which is dependent on folic acid as a coenzyme, and the salvage pathway, which is dependent on the enzyme hypoxanthine phosphoribosyltransferase (HPRT). Mutant tumor lines that are HPRT deficient depend on the de novo pathway for survival. In the conventional HAT selection medium, such HPRT-deficient tumor cells will die because the aminopterin blocks de novo nucleotide synthesis. Hybrid cells will survive if they have acquired the enzyme HPRT from the genes of the normal-cell and are able to utilize the salvage pathway in HAT selection. Aminopterin blocks both purine and pyrimidine synthesis and, consequently, hypoxan-. thine and thymidine are necessary for hybrid cell survival.
Azaserine is an alkylating agent produced by the bacterium Streptomyces fragilis (16) . It is a diazo analog of L-glutamine and, more importantly, its main action is irreversible binding to various L-glutamine amidotransferases that are necessary in de novo purine synthesis. Its effect on pyrimidine synthesis is minimal. Therefore, in a selection medium containing azaserine only, hypoxanthine is necessary for the salvage pathway whereas exogenous thymidine is not. Thus, the problem of thymidine inhibition is avoided with this selection method. In preliminary studies (data not shown), this system was tried with a murine B-B fusion and was successful in selecting murine hybrids. In the human system, T-T hybrids have been produced with the mutant T-cell line J3R7. AH selection resulted in earlier appearance and greater number of hybrids ( Table 1 ). The earlier appearance of hybrids in the J3R7 fusion in comparison with fusions with CEMT3 may also be influenced by the more rapid growth rate of the J3R7 mutant line.
After 4 months of continuous culture, there has been no detectable chromosomal. loss or decrease in IL-2 activity in the supernatants from the J3R7-derived hybrids. Although the question of long-term stability of these hybrids requires continued surveillance, the use of AH selection appears to offer significant advantages over the traditional HAT medium in the selection of T-T hybrids. We believe that the approach described here should allow sufficient production oflymphokines for in vitro and in vivo studies oftheir roles in immunoregulation.
